Lund University, Sweden

Prof. Angela Cenci Nilsson, MD, PhD

Prof. Cenci Nilsson is a renowned neurobiologist and neurologist in the field of Parkinson’s disease. Since 2005, she leads the Basal Ganglia Pathophysiology team at Lund University, and she is an advisor on funding institutions and international research organizations. She also serves on the Editorial Boards of several scientific journals.

Collaboration: action of 5-HT1A agonists in models of Parkinson’s disease

Dr. Andrew McCreary, PhD

Dr. McCreary is a neuropsychopharmacologist, with a recognized track record in drug discovery of novel antiparkinsonian and antipsychotic agents. He has strong industrial experience and is currently neurochemistry and pharmacokinetics Project Leader.

Collaboration: action of serotonin 5-HT1A agonists in models of Parkinson’s disease

Binghamton University,
The State University of New York

Dr. Christopher Bishop, Ph.D.

Dr. Bishop leads a research group focusing on how brain plasticity in the diseased brain, especially Parkinson's disease, may provide novel targets for improved treatment. His preclinical investigations into the role of 5-HT in L-DOPA-induced dyskinesia have informed several current translational targets in the clinical population. 

Collaboration: anti-dyskinetic activity of serotonin 5-HT1A receptor ‘biased’ agonists.

Jagiellonian University,
Krakow, Poland

Prof. Anna Wesołowska, PhD

Prof. Anna Wesołowska is an expert behavioral pharmacologist, particularly in the area of serotonergic receptors. She has a wide experience in investigating the role of 5-HT receptor subtypes as well as in identification of novel serotonergic ligands.

Collaboration: drug discovery of novel chemical entities targeting mood deficits and psychosis.

University of Columbia,
New York City, USA

Prof. David E. Leonardo, MD, PhD

Prof. Leonardo leads a research team focusing on how temporal factors and genetic risk impact the expression of mental illness. He is an expert on the role of serotonin 5-HT1A receptor in regulating vulnerability to stress and depressive states.

Collaboration: influence of serotonin 5-HT1A receptor ‘biased’ agonists on anxiety and depression.

University of Bristol,
United Kingdom

Prof. Julian Paton, PhD 

Prof. Paton holds a Chair of Physiology and is an expert in respiratory and cardiovascular function, with particular interest in Rett syndrome. He has published over 250 research articles and is a member of the Editorial Board of the Journal of Physiology.

Dr. Ana Abdala Sheik, PhD

Dr Abdala Sheik is an expert on the neural circuits involved in generating respiratory rhythm, sympathetic activity and blood pressure. In particular, her work has advanced understanding of 5-HT1A receptors in Rett syndrome.

Collaboration: action of serotonin 5-HT1A agonists in transgenic mouse models of Rett syndrome

Prof. Steven Petrou, PhD

Prof. Petrou leads an epilepsy research team that tests transgenic mouse models. He is expert on the action of ion channels associated with neuronal signaling and is member of the Editorial Board of Neurobiology of Disease.

Collaboration: mechanism of action of potential novel analgesic agents

Maastricht University,
The Netherlands

Dr. Jos Prickaerts, PhD

Dr. Prickaers leads a research group focusing on signal transduction and plasticity in affective disorders and cognitive processes. He has previously conducted drug discovery programs in a pharmaceutical industry context.

Collaboration: procognitive activity of serotonin 5-HT1A receptor ‘biased’ agonists.

University of Newcastle,
United Kingdom

 Dr Mohammed Shoaib, PhD

Dr Shoaib is expert in the field of nicotine dependence with emphasis on cognitive measures associated with neuropsychiatric disorders. He has served as an executive Council member for the British Association for Psychopharmacology (BAP) and as Program Chair for the Society for Research on Nicotine and Tobacco in Europe (SRNT-E).

Collaboration: effects of 5-HT1A receptor ‘biased’ agonists on nicotine-induced cognitive deficits

Prof. Luc Zimmer, PharmD, PhD

Prof. Zimmer holds a chair in neuropharmacology at the Université Claude Bernard Lyon 1 and leads the brain imaging laboratory within the CERMEP-Imaging platform at the University Hospital of Lyon. He is expert in the development of serotonergic PET radiotracers.

Collaboration: development of novel serotonin 5-HT1A receptor PET radiotracers